Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

s trial will be presented by the lead investigator, Prof. Peter Stalmans, at the Euretina Conference on May 23, in Vienna. The third and fourth cohorts from this trial will be presented at major ophthalmic conferences in the second half of 2008.

- Results are expected from the Phase II MITI IV trial in mid 2008.

This Phase II trial is evaluating the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients. Once these data from the study have been reviewed, a decision will be made on the future development plans for microplasmin in the treatment of acute stroke.

It is ThromboGenics' current intention that it will only move forward with the development of microplasmin for the treatment of stroke in conjunction with a partner. This intention is based on both the risks and cost associated with the development of new stroke therapies and the Company's desire to invest in its other attractive pipeline product candidates, such as microplasmin in the treatment of back of the eye diseases and TB-403.

TB-403

- Results from the initial Phase I trial of this novel anti-cancer agent in healthy volunteers are expected in the third quarter of 2008.

Following the successful completion of this initial Phase I study, ThromboGenics expects to begin a Phase Ib trial with TB-403 in end stage cancer patients in mid 2008. This study, which will recruit approximately 24 patients, is designed to provide both safety data on TB-403 when used in cancer patients and some early efficacy data on the product.

TB-402

- Top line results of the interaction studies to be announced by mid-2008.

TB-402 is being developed as an anti-coagulant for the prevention of deep vein thrombosis (DVT) after orthopaedic surgery and prevention of venous emboli in patients with atrial fibrillation. It is a novel human antibody that partially blocks Factor VIII, an essential blood clotting factor. The implicat
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
Breaking Biology Technology:Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Libreville International Conference 2-3 June 2010 2
...search,organization, is pleased to announce that l...r for the Czech Republic, received GCPj,s "Best,Cl...remony was held in,London,s historic Gibson Hall. ...panel of judges who,reviewed his achievements in t...nical trials. The judging panel was composed of a ...
...a,leading, global full-service clinical research o...ident and Chief Financial Officer Karl,"Buzz" Bren...h Annual,Healthcare Conference at the Grand Hyatt ...ity, Sept. 10-11, 2007. Kendle,s presentation is,s...n Time. (Logo: http://www.newscom.com/cgi-bin/pr...
...d of,Pharmacy has approved a 14-module, eight-hour...ewood Pharmacy. The program was developed by the,c...Department. Upon,completion of the program, each t...rate a high level of competence in all state rules... Portability and Accountability Act,(HIPAA) regula...
Other Biology Technology:Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year 2Kendle to Present at Bear Stearns 20th Annual Healthcare Conference 2NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program 2NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program 3
(Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou
(Date:12/3/2009)Our ability to learn new information and adapt to changes in our daily environment, as well as to retain lifelong memories, appears to lie in the minute junctions where nerve cells communicate, accord
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
Breaking Biology News(10 mins):How nutrition affects healthy aging 2Lifelong memories linked to stable nerve connections 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 33SBio Inc Announces Results of Annual General Meeting 5580 1Psychiatric disorders and sexual trauma are associated with lower urinary tract symptoms 59785 1Psychiatric disorders and sexual trauma are associated with lower urinary tract symptoms 59785 2SURF CRUISE CUP 2009 59783 1SURF CRUISE CUP 2009 59783 2
...heres no doubt about it ... the platypus is one od...adaptations like webbed feet to fit its aquatic li...the platypus represents for many a patchwork of ev...g with an international consortium of scientists l... Louis, Mo., has taken this theory to an entirely ...
...onal commerce of ornamental stones has grown all o...ed solid support to the aesthetics of natural ston...on. , Marble is, undoubtedly, the ornamental ston...vilizations have architectural or sculptural works...ir historic heritage. Despite this, nowadays we ha...
...ghts: , Mechanism of action of compound found to... The findings may lead researchers to develop pot...e, amyotrophic lateral sclerosis, Huntingtons dise...nant gliomas , RICHMOND, Va. (May 9, 2008) Virg...overed how an antibiotic works to modulate the act...
Other Biology News:First analysis of platypus genome may impact disease prevention 2Development of new techniques to understand marble quality and durability 2Researchers uncover mechanism of action of antibiotic able to reduce neuronal cell death in brain 2Researchers uncover mechanism of action of antibiotic able to reduce neuronal cell death in brain 3
...ore tubes to 1 outflow Single-cell and patch deli...everal millisecond) solution change Very small de...on , Solid construction 360, 250 and 100 micro...ny micromanipulator Available in 4, 8, and 16 cha...
steadylite plus Reporter Gene Assay System, 100 mL from PerkinElmer
pTRI-GAPDH-Human (316 bp protected fragment) from Ambion
...nsect Medium is formuatled for the growth of insec... Insect Mediu, Unsupplemented is ideal for transfe...rosylate, and yeastolate, which can interfere with... is formulated for general growth and maintenance ...
Biology Products: